Mariam Pkhaladze MD.

• 2000-2006 –Tbilisi State Medical University, the Faculty of Medicine;
• 2007-2011 – Institute of Postgraduate Medical Education and Continuous Professional Development – Pediatric Endocrinology, licensed doctor.

• 12.2007-10.06.2008 – Traineeship at the Health Department of the Ministry of Labor, Health and Social Affairs of Georgia;
• 12.2012-present – G. Zhvania Pediatric Academic Clinic, pediatric endocrinologist, head of the diabetes school;
• 2014-2018 – Rustavi diagnostic center No. 1;
• 2014-present – MediMedi Medical Center;
• 2015-2018 – Enmedic Clinic;
• 2015-present – Association for the Protection of Children with Diabetes;
• 2020-present – Medsi Clinic.

• March 25-29, 2019 – Certificate of the Institute of Postgraduate Medical Education and Continuous Professional Development of TSM, the training program for teachers (trainers).

• 2010-2011 – European Association for the Study of Diabetes (EASD);
• 2014-present – Co-founder of the Georgian Society of Pediatric Endocrinology;
• 2020-present – Member of the International Association of Georgian Doctors.

• Since 2004 – Co-principal investigator of the clinical trial “Weekly randomized, open-label, phase II trial to evaluate the safety of three doses of TV-1106 and dose adjustment, compared with recombinant human growth hormone (Genotropin) treatment in previously untreated pre-pubertal children with growth hormone deficiency”.
• Since 2005 – Co-principal investigator – “Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial in pediatric patients with type 2 diabetes mellitus”.
• Since 2005 – Co-principal investigator of a clinical trial to evaluate the safety and efficacy of Sitagliptin in pediatric patients with type 2 diabetes mellitus with poor glycemic control.
• Since 2005 – Co-principal investigator – “Multicenter, randomized, open-label, active-controlled, parallel group Phase III trial in which the safety, tolerability and efficacy of a daily dose of human growth hormone versus daily standard human growth hormone replacement therapy is evaluated within 52 weeks in pre-pubertal children with growth hormone deficiency”.

• 2017 – Diabetes Mellitus in Children and Adolescents, Tbilisi;
• 2016 – How to Deal with Diabetes, Tbilisi.

Georgian – Native
Russian – Fluent
English – Fluent